Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 26;6(4):00408-2020.
doi: 10.1183/23120541.00408-2020. eCollection 2020 Oct.

Multicentre feasibility of multiple-breath washout in preschool children with cystic fibrosis and other lung diseases

Affiliations

Multicentre feasibility of multiple-breath washout in preschool children with cystic fibrosis and other lung diseases

Mirjam Stahl et al. ERJ Open Res. .

Abstract

Background: Multiple-breath washout (MBW)-derived lung clearance index (LCI) detects early cystic fibrosis (CF) lung disease. LCI was used as an end-point in single- and multicentre settings at highly experienced MBW centres in preschool children. However, multicentre feasibility of MBW in children aged 2-6 years, including centres naïve to this technique, has not been determined systematically.

Methods: Following central training, 91 standardised nitrogen MBW investigations were performed in 74 awake preschool children (15 controls, 46 with CF, and 13 with other lung diseases), mean age 4.6±0.9 years at investigation, using a commercially available device across five centres in Germany (three experienced, two naïve to the performance in awake preschool children) with central data analysis. Each MBW investigation consisted of several measurements.

Results: Overall success rate of MBW investigations was 82.4% ranging from 70.6% to 94.1% across study sites. The number of measurements per investigation was significantly different between sites ranging from 3.7 to 6.2 (p<0.01), while the mean number of successful measurements per investigation was comparable with 2.1 (range, 1.9 to 2.5; p=0.46). In children with CF, the LCI was increased (median 8.2, range, 6.7-15.5) compared to controls (median 7.3, range 6.5-8.3; p<0.01), and comparable to children with other lung diseases (median 7.9, range, 6.6-13.9; p=0.95).

Conclusion: This study demonstrates that multicentre MBW in awake preschool children is feasible, even in centres previously naïve, with central coordination to assure standardised training, quality control and supervision. Our results support the use of LCI as multicentre end-point in clinical trials in awake preschoolers with CF.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: M. Stahl reports grants from Mukoviszidose eV, personal fees from Vertex Pharmaceuticals and grants from Christiane Herzog Foundation, during the conduct of the study. Conflict of interest: C. Joachim has nothing to disclose. Conflict of interest: I. Kirsch has nothing to disclose. Conflict of interest: T. Uselmann has nothing to disclose. Conflict of interest: Y. Yu has nothing to disclose. Conflict of interest: N. Alfeis has nothing to disclose. Conflict of interest: C. Berger has nothing to disclose. Conflict of interest: R. Minso has nothing to disclose. Conflict of interest: I. Rudolf has nothing to disclose. Conflict of interest: C. Stolpe has nothing to disclose. Conflict of interest: X. Bovermann has nothing to disclose. Conflict of interest: L. Liboschik has nothing to disclose. Conflict of interest: A. Steinmetz has nothing to disclose. Conflict of interest: D. Tennhardt has nothing to disclose. Conflict of interest: F. Dörfler has nothing to disclose. Conflict of interest: J. Röhmel has nothing to disclose. Conflict of interest: K. Unorji-Frank has nothing to disclose. Conflict of interest: C. Rückes-Nilges has nothing to disclose. Conflict of interest: B. von Stoutz has nothing to disclose. Conflict of interest: L. Naehrlich reports that he has received institutional fees for site participation in clinical trials from Vertex Pharmaceuticals. Conflict of interest: M.V. Kopp has nothing to disclose. Conflict of interest: A-M. Dittrich has nothing to disclose. Conflict of interest: O. Sommerburg has nothing to disclose. Conflict of interest: M.A. Mall reports grants from the German Federal Ministry of Education and Research and the Einstein Foundation Berlin during the conduct of the study; advisory board, consultancy, lecture and clinical trial fees from Boehringer Ingelheim, advisory board and consultancy fees from Arrowhead Pharmaceuticals, advisory board, consultancy, lecture and clinical trial fees from Vertex Pharmaceuticals, advisory board and consultancy fees from Santhera, consultancy fees from Galapagos and Sterna Biologicals, advisory board and consultancy fees from Enterprise Therapeutics, and consultancy fees from Antabio, outside the submitted work.

Figures

FIGURE 1
FIGURE 1
Success rates of multicentre MBW investigations in awake preschool children without lung disease (control), with CF and with other lung diseases. Summary of success rates for technically acceptable MBW investigations for the total study population and for individual study sites. MBW: multiple-breath washout; CF: cystic fibrosis; ARCN: CF Center at Airway Research Center North; BREATH: CF Center at Biomedical Research in Endstage and Obstructive Lung Disease Hannover; TLRC: CF Center at Translational Lung Research Center Heidelberg; UGMLC: CF Center at Universities of Giessen and Marburg Lung Center; Berlin: CF Center at Charité - Universitätsmedizin Berlin.
FIGURE 2
FIGURE 2
Multiple-breath washout (MBW) success rates according to age. MBW investigations are grouped according to the age of the children at time of investigation, where “2” stands for the age group of children from 2.0 to 2.9 years of age and so on. The Pearson correlation coefficient r and p-values are provided.
FIGURE 3
FIGURE 3
Summary of lung clearance index (LCI) in preschool children without lung disease (control), with cystic fibrosis (CF) and with other lung diseases in the multicentre setting. Dotted line represents upper limit of normal of 8.3. Open circles (CF Center at Airway Research Center North), closed circles (CF Center at Biomedical Research in Endstage and Obstructive Lung Disease Hannover), open triangles (CF Center at Translational Lung Research Center Heidelberg), closed triangles (CF Center at Universities of Giessen and Marburg Lung Center) and open squares (CF Center at Charité - Universitätsmedizin Berlin) represent data from individual children from the respective study site. Solid horizontal lines represent median values for each group. **: p<0.01 versus control group.

Similar articles

Cited by

References

    1. Bell SC, Mall MA, Gutierrez H, et al. . The future of cystic fibrosis care: a global perspective. Lancet Respir Med 2020; 8: 65–124. doi:10.1016/S2213-2600(19)30337-6 - DOI - PMC - PubMed
    1. Grasemann H, Ratjen F. Early lung disease in cystic fibrosis. Lancet Respir Med 2013; 1: 148–157. doi:10.1016/S2213-2600(13)70026-2 - DOI - PubMed
    1. Mall MA, Mayer-Hamblett N, Rowe SM. Cystic fibrosis: emergence of highly effective targeted therapeutics and potential clinical implications. Am J Respir Crit Care Med 2020; 201: 1193–1208. doi:10.1164/rccm.201910-1943SO - DOI - PMC - PubMed
    1. Mall MA, Graeber SY, Stahl M, et al. . Early cystic fibrosis lung disease: role of airway surface dehydration and lessons from preventive rehydration therapies in mice. Int J Biochem Cell Biol 2014; 52: 174–179. doi:10.1016/j.biocel.2014.02.006 - DOI - PubMed
    1. Mall MA, Stahl M, Graeber SY, et al. . Early detection and sensitive monitoring of CF lung disease: prospects of improved and safer imaging. Pediatr Pulmonol 2016; 51: S49–S60. doi:10.1002/ppul.23537 - DOI - PubMed